{"links":{"html":"https://www.erudio.com/reports/rmc-9805-001-nct06040541","json":"https://www.erudio.com/reports/rmc-9805-001-nct06040541.json","markdown":"https://www.erudio.com/reports/rmc-9805-001-nct06040541.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"rmc-9805-001-06040541"}},"request":"https://www.erudio.com/contact?report=rmc-9805-001-06040541"},"offer":{"cited_commentary_sources":26,"verified_hcp_statements":71,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":12,"optional":true,"price_per_verified_person_usd":15,"price_usd":180,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"rmc-9805-001-nct06040541"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=rmc-9805-001-06040541","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/rmc-9805-001-nct06040541","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T09:40:40.997371Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":0},"aspects":[{"claim_count":4,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":3,"title":"Primary endpoint: Adverse events"},{"claim_count":4,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":3,"title":"Primary endpoint: Dose Limiting Toxicities"},{"claim_count":2,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":2,"title":"Secondary endpoints"},{"claim_count":7,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":1,"title":"Population and setting"},{"claim_count":10,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":6,"title":"The comparison"},{"claim_count":13,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":9,"title":"Safety and tolerability"},{"claim_count":6,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":2,"title":"Design and conduct"},{"claim_count":9,"coverage":"discussed","id":"A1","source_count":7,"title":"Could dual blockade become a chemotherapy-free PDAC option?"},{"claim_count":12,"coverage":"discussed","id":"A2","source_count":5,"title":"NSCLC durability, unmet need and the docetaxel benchmark"},{"claim_count":2,"coverage":"discussed","id":"A3","source_count":1,"title":"CNS activity cannot yet be inferred"},{"claim_count":16,"coverage":"discussed","id":"A4","source_count":9,"title":"Target validation, mechanism and preclinical response displays"},{"claim_count":8,"coverage":"discussed","id":"A5","source_count":4,"title":"Early confidence, response-rate skepticism and conditional combination rationales"},{"claim_count":3,"coverage":"discussed","id":"A6","source_count":3,"title":"Geographic access, trial choice and comparative information needs"}],"counts":{"cited_sources":26,"claims_by_expression_type":{"comparison":6,"experience":1,"interpretation":23,"opinion":9,"primary_context":1,"question":7,"restatement":15,"uncertainty":3,"unspecified":6},"claims_by_kind":{"source_observation":71},"clinician_statements":7,"evidence_units":63,"findings":8,"organisational_accounts":5,"people_cited":17,"people_identity_verified":12,"people_total":17,"screened_sources":51,"verified_claims":71},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":0,"views":7},"has_counterview":true,"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":7,"passages":8,"sources":7,"sources_by_kind":{"commentary":7}},"title":"A chemotherapy-free PDAC option is an important question, not an established treatment conclusion"},{"id":"F2","structure":{"claims":19,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":8,"views":7},"has_counterview":true,"limitations":4,"links":{"context":0,"support":20},"ma_question":true,"named_voices":7,"passages":13,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Two speakers welcome the NSCLC findings; the presenter's docetaxel comparison is contextual"},{"id":"F3","structure":{"claims":16,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":3,"views":10},"has_counterview":true,"limitations":4,"links":{"context":0,"support":17},"ma_question":true,"named_voices":8,"passages":14,"sources":8,"sources_by_kind":{"commentary":7,"media":1}},"title":"Favorable tolerability is regimen-specific and does not mean absence of consequential toxicity"},{"id":"F4","structure":{"claims":14,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":2,"views":10},"has_counterview":true,"limitations":5,"links":{"context":1,"support":14},"ma_question":true,"named_voices":8,"passages":11,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Combination development has a rationale, but early response expectations include explicit skepticism"},{"id":"F5","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":3,"views":1},"has_counterview":false,"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":1,"passages":7,"sources":1,"sources_by_kind":{"media":1}},"title":"Smoking phenotype and treated brain metastases raise applicability questions, not subgroup answers"},{"id":"F6","structure":{"claims":16,"claims_by_group":{"comparisons":1,"experience":1,"questions":2,"restated":6,"views":6},"has_counterview":true,"limitations":4,"links":{"context":2,"support":23},"ma_question":true,"named_voices":8,"passages":19,"sources":8,"sources_by_kind":{"commentary":7,"media":1}},"title":"Target-validation enthusiasm coexists with careful separation of model, molecular and clinical evidence"},{"id":"F7","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":0,"views":1},"has_counterview":false,"limitations":3,"links":{"context":0,"support":3},"ma_question":true,"named_voices":3,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Access and comparative trial choice remain practical questions"},{"id":"F8","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":1},"has_counterview":false,"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":0,"passages":1,"sources":1,"sources_by_kind":{"media":1}},"title":"A general PDAC video connects precision-oncology optimism with genomic profiling"}],"medical_affairs_question":"What evidence would justify choosing dual blockade rather than chemotherapy or single-agent RAS inhibition, for which patients and with which tolerability trade-offs?","sections":{"analysis":[{"id":"section-1","level":2,"title":"A chemotherapy-free PDAC option remains a confirmatory-evidence question"},{"id":"section-2","level":2,"title":"Two speakers praise the NSCLC findings; the docetaxel comparison remains contextual"},{"id":"section-3","level":2,"title":"Tolerability needs regimen-specific qualification"},{"id":"section-4","level":2,"title":"Combination rationale should not erase early uncertainty"},{"id":"section-5","level":2,"title":"Population questions remain open for smoking biology and CNS disease"},{"id":"section-6","level":2,"title":"Translational promise is not interchangeable with human comparative efficacy"},{"id":"section-7","level":2,"title":"Access and trial comparison are unresolved practical needs"},{"id":"section-8","level":2,"title":"A general PDAC video raises genomic profiling as a selection issue"},{"id":"section-9","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, parallel, phase1","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":1}],"id":"T1","label":"Primary endpoint: Adverse events"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F3","shared_claims":3}],"id":"T2","label":"Primary endpoint: Dose Limiting Toxicities"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F5","shared_claims":6}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":5},{"id":"F6","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":10},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":1}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T09:40:40.997371Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T14:44:57Z","record_hash":"0bb6cf84c67e1f456b5d2a3c8b370760df2eef973dcefc311ed166caef6e340e","release_hash":"f7ae32e1fef84799723178547d433434c7cf90ddb4d0f96b7de4408459501015","report_id":"erudio-nct06040541","run_id":"5a98dfba-78ec-4fea-8c19-fea9e783021c","schema_version":"5.0","slug":"rmc-9805-001-06040541","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Clinician commentary on RMC-9805-001 in the sources reviewed for this edition leads to one open question: What evidence would justify choosing dual blockade rather than chemotherapy or single-agent RAS inhibition, for which patients and with which tolerability trade-offs? Its leading findings: (1) A chemotherapy-free PDAC option is an important question, not an established treatment conclusion. (2) two speakers welcome the NSCLC findings; the presenter's docetaxel comparison is contextual. (3) favorable tolerability is regimen-specific and does not mean absence of consequential toxicity. 5 more findings follow. 51 sources screened, 26 cited; not all HCPs or all public discussion.","meta_description":"51 sources screened · 71 verified statements (7 from clinicians verified by NPI or staff page) from 26 sources · 8 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-29T14:44:57Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":51},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on mutation-defined eligibility for investigational combination treatments in non-small cell lung cancer.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","44 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits apply, so some matching discussion may be missing.","The report describes the sources reviewed for this edition, not all HCPs or all public discussion. Some passages were not fully assessed, and many potentially relevant sources without an explicit trial name were not read.","Unnamed references and transcription variants may be missing. One potentially relevant statement could not be used because its molecular-eligibility wording was unreliable.","Clinical roles are not established for several named social-media authors. Source descriptions such as MD or PhD are not independent verification of a clinical role, and an organizational relay is not necessarily its author's own clinical view.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Repeated posts, reposts and multiple unidentified turns do not establish independent HCP agreement or consensus.","Comments on early RMC-9805 work or the same treatment setting that do not name the trial are attributed context, not additional identified results from NCT06040541. A general PDAC video's genomic-profiling recommendation is selection context, not G12D efficacy evidence.","Early-phase, selected-population and cross-study observations do not establish superiority over chemotherapy, docetaxel or a single RAS inhibitor. Predictions and conditional efficacy thresholds remain predictions and conditions.","No protocol, matching regulatory label or trial results publication is included. Statements about FDA designation and dose-selection consultation remain attributed presentation remarks."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":4,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":19,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":26},"count":26,"evidence_window":{"end":"2026-07-06","start":"2023-09-15"},"retrieval_snapshot":"2026-10-29T08:40:48.497715Z","timeline":[{"count":1,"week":"2023-W37"},{"count":1,"week":"2024-W14"},{"count":1,"week":"2024-W30"},{"count":2,"week":"2024-W43"},{"count":1,"week":"2024-W44"},{"count":1,"week":"2025-W17"},{"count":2,"week":"2025-W18"},{"count":1,"week":"2025-W35"},{"count":2,"week":"2026-W13"},{"count":2,"week":"2026-W16"},{"count":3,"week":"2026-W17"},{"count":1,"week":"2026-W18"},{"count":6,"week":"2026-W27"},{"count":2,"week":"2026-W28"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06040541:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06040541:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:40056080","quote_policy":"short_quote_link_out"},{"id":"pubmed:40705880","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-rlwboxuuhaxwudp7iakmkoaw-3lntldd3j4k2z","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7452248046337298433","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7456276403257344000","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7478824875424468992","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7479751074661376000","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1702755089075806487:be26c767-edd8-4af4-ba95-15390d012aab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1704088711531540552:95f36801-bba2-4771-a252-ee203e10eb7e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1704119323969933329:8d289994-ec77-441d-9443-0d368620eb51","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1704125103448186984:ae7da931-8471-45f5-b14d-2f5b1f7559aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1704181633677676999:adffeb3a-06da-4d65-a627-2c5e79926cb4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1706084236430598581:2e1f8a58-1f6c-46f2-9b51-477b09c99ab4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1706352938334015540:46d3d4ba-ec45-4fb4-bbdb-f1f2e0e07fd0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1706946716019101891:d8cfe852-189a-4dcc-820a-ca5152e71b11","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1753162786677596640:4402894d-cacc-41ab-ad10-9b5732ecad3e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1777078823051477346:91e716cf-8b13-468c-8b33-453f8da8d9a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1777114168337776938:3d1c40ba-cdad-4def-94f3-99262c50b037","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1816551928178049290:af2dc8ab-0039-4d30-bffe-5850bda529d3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1849767774354112922:063cee8e-2d1e-41a0-a5c0-a7d29c057b0e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1849769427341893961:54519064-01ae-44a1-9aa5-269b1f6f3dbc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1849815075315429702:5c7a905e-7eff-4c1c-9163-fbb454616567","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1850895340280442939:cbd2a907-ddd1-46ee-98be-cc436bda776d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1869426207181402461:28bb4daf-166c-4231-a261-5eabeac45777","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1890521445605781784:3d59f824-16f4-40e9-874b-f0f0247e54b4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915375178588029409:15901e62-bb3d-4905-ada7-7d4eef16fc9d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915805757792043297:d0f7094b-8846-4592-bcb1-61ff277beaf2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1916812184036024522:f4e8f817-0962-4c51-8469-b455f97523e9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009376777211199935:a93ab4a0-8d45-4a67-8e1c-9fcf887c036b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2010743581640692048:a36d85ee-671c-40d4-9719-793f09ff7426","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2035908107608756584:440154fb-e108-4898-97a3-49073d941c85","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2035912152067027051:74411277-b4ab-49da-97ec-08cc79cc0f65","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2044041062361247849:82f7104b-cb60-4b91-981a-f8948f48622c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2045968129281675624:eb87d213-5790-4c51-9b1d-d8b201dbe332","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2046198436735922430:35149faf-a8d1-479c-b6bb-f0af0aea79dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2046347853149393127:85e5f6e9-43d6-4cc0-a055-f02a44a4c582","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047072380581802462:d7a9120f-13d8-41d9-8f09-066c8f4744e0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047584912363094065:6d022023-7357-45a5-9eb9-c952de808a7e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072666259091599804:49282899-0f8f-4d0d-8777-9d27bf3dccbb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072666714072813619:1fe232fc-c687-453d-a428-c9b2c60c6042","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072671488256176392:d2a293f4-9df5-49ac-89b4-2499d7cc79fd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072672471073878189:2979a34b-2e2f-4944-8fba-739e580fe9c7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072672927367987705:15ec3614-c7ab-4f31-b6b8-7d07e13e2aca","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072697000508768387:a40a544d-7b92-4f4d-8a28-7d339a492007","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2073495778799292464:56f89a70-e889-4348-82db-7be697f05237","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2073982918716993676:0d395f83-b75e-4ba7-81dc-f2712839935c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2073984065070612826:75ebc89a-7ab5-46de-b745-05468bf0e2b7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2074514869119050118:315b9e1e-8011-4b38-8c78-475016e97f62","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2084337827639349662:6403a887-f232-4339-bbd4-d3c27ae39e77","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099554434347147266:18c06df8-4b67-4fbc-9a3e-8655f33dc7c5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103869620394557742:29936c21-2048-453b-b473-f1b8391a088a","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:88QMDLrlNlw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ZRMuKfPC0d8","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":4,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":44,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":51},"count":51,"evidence_window":{"end":"2026-09-26","start":"2023-09-15"},"retrieval_snapshot":"2026-10-29T08:40:48.497715Z","timeline":[{"count":1,"week":"2023-W37"},{"count":5,"week":"2023-W38"},{"count":2,"week":"2023-W39"},{"count":1,"week":"2024-W05"},{"count":2,"week":"2024-W14"},{"count":1,"week":"2024-W30"},{"count":3,"week":"2024-W43"},{"count":1,"week":"2024-W44"},{"count":1,"week":"2024-W51"},{"count":1,"week":"2025-W07"},{"count":2,"week":"2025-W17"},{"count":2,"week":"2025-W18"},{"count":1,"week":"2025-W35"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W03"},{"count":2,"week":"2026-W13"},{"count":3,"week":"2026-W16"},{"count":5,"week":"2026-W17"},{"count":1,"week":"2026-W18"},{"count":8,"week":"2026-W27"},{"count":4,"week":"2026-W28"},{"count":1,"week":"2026-W32"},{"count":1,"week":"2026-W38"},{"count":1,"week":"2026-W39"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: rmc-9805","status":"unmapped"},{"reason":"Unmapped registry intervention: rmc-6236","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Colorectal cancer","slug":"colorectal-cancer"},{"reason":"Unmapped registry condition: Pancreatic Ductal Adenocarcinoma (PDAC)","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Advanced solid tumors","slug":"advanced-solid-tumors"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"RMC-9805-001","aliases":["RMC-9805-001","Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors"],"brief_title":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Advanced Solid Tumors"],"enrollment":{"count":604,"type":"ESTIMATED"},"interventions":[{"name":"RMC-9805","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"RMC-6236","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06040541","official_title":"Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors","overall_status":"RECRUITING","phase":["PHASE1"],"primary_completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"primary_endpoints":[{"description":"Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs and clinically significant changes in laboratory values, ECGs, and vital signs","measure":"Adverse events","timeFrame":"Up to 3 years"},{"description":"Number of participants with Dose Limiting Toxicities (DLTs)","measure":"Dose Limiting Toxicities","timeFrame":"21 days"}],"registered_date":{"date":"2023-09-15","type":"ACTUAL"},"registry_last_updated":"2026-06-03","registry_url":"https://clinicaltrials.gov/study/NCT06040541","short_name":"RMC-9805-001","short_name_basis":"canonical_name","sponsor":"Revolution Medicines, Inc.","start_date":{"date":"2023-09-07","type":"ACTUAL"},"study_design":"interventional, non randomized, parallel, phase1","study_ids":[{"id":"RMC-9805-001","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}